1140:
Vemurafenib, plus
Obinutuzumab, in patients with previously untreated classical hairy cell leukemia. A separate clinical study treatment with only Vemurafenib (or monotherarpy) demonstrated high response rates in relapsed/refractory (R/R) hairy cell leukemia (HCL), achieving an overall response rate of 86%, including 33% complete response (CR) and 53% partial response. However, after a median follow-up of 40 months, 21 of 31 responders (68%) experienced relapse with a median relapse-free survival (RFS) of 19 months (range, 12.5-53.9 months).
613:
590:
38:
29:
6716:
780:
1139:
Foundation supported the discovery of the BRAF mutation in classic HCL. This discovery charted a new path forward for many patients. It improved diagnosis and opened the door for additional therapies to be used in managing HCL. In a phase II clinical trial, Memorial Sloan
Kettering is testing
948:). About 60% of melanomas have this mutation. It also has efficacy against the rarer BRAF V600K mutation. Melanoma cells without these mutations are not inhibited by vemurafenib; the drug paradoxically stimulates normal BRAF and may promote tumor growth in such cases.
1012:, vemurafenib (then known as PLX4032) was able to reduce numbers of cancer cells in over half of a group of 16 patients with advanced melanoma. The treated group had a median increased survival time of 6 months over the control group.
999:
in 58% of patients, skin rash in 52%, and photosensitivity in 52%. In order to better manage side effects some form of dose modification was necessary in 45% of patients. The median daily dose was 1750 mg, 91% of the MTD.
1252:
Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C (May 2008). "BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells".
994:
At the maximum tolerated dose (MTD) of 960 mg twice a day 31% of patients get skin lesions that may need surgical removal. The BRIM-2 trial investigated 132 patients; the most common adverse events were
2351:
301:
3782:
1728:
205:
694:
2127:"Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study"
2066:
256:
1889:
6736:
2035:
1801:
2344:
5697:
3775:
6657:
736:
InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)
6781:
2314:
2174:
1911:
137:
708:
6313:
5461:
2337:
1040:
In June 2011, positive results were reported from the phase III BRIM3 BRAF-mutation melanoma study. The BRIM3 trial reported good updated results in 2012.
1015:
A second phase I study, in patients with a V600E mutation in B-Raf, ~80% showed partial to complete regression. The regression lasted from 2 to 18 months.
1486:
5078:
3768:
870:
1620:
5136:
188:
5998:
5688:
972:
1388:"PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells"
5293:
3343:
2986:
1992:
Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P (November 2012). "Vemurafenib: the first drug approved for BRAF-mutant cancer".
1736:
4278:
3961:
1079:
Vemurafenib was approved in the United States for the treatment of late-stage melanoma in August 2011, making it the first drug designed using
795:= red) complexed with vemurafenib (spheres, carbon = white, oxygen = red, nitrogen = blue, chlorine = green, fluorine = cyan, sulfur = yellow).
6786:
6676:
6626:
6597:
6544:
5031:
4898:
6355:
6351:
6347:
6343:
3896:
3880:
2479:
1972:"FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a Deadly Form of Skin Cancer"
4624:
4543:
4410:
4327:
2074:
6339:
3457:
6746:
6028:
5147:
4707:
4318:
883:
728:
201:
102:
1861:
3976:
3920:
3911:
2877:
2403:
2043:
6550:
1037:) in patients with previously untreated metastatic melanoma showed an improved rates of overall and progression-free survival.
356:
286:
169:
1957:
6637:
6613:
5753:
5309:
5172:
1932:
1809:
6603:
1080:
6706:
2067:"First Personalized Cancer Medicine Allows Patients with Deadly Form of Metastatic Melanoma to Live Significantly Longer"
6647:
5043:
4925:
4915:
3223:
2102:
1108:
1052:
481:
1112:
5993:
2380:
1009:
569:
6018:
3404:
2252:"Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy"
1971:
6756:
6751:
6632:
4458:
3529:
3378:
3127:
2629:
6013:
6741:
6540:
2854:
2720:
2433:
183:
6761:
4724:
4640:
4559:
4426:
4343:
2864:
2390:
982:
828:
4158:
1907:
430:
6791:
6324:
4071:
3946:
2360:
1729:"Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer"
242:
6003:
2096:
608:
6796:
6608:
6224:
6128:
5988:
5748:
5167:
4153:
3791:
3232:
2715:
2444:
530:
6776:
6771:
6766:
6682:
4879:
4523:
4163:
3802:
2790:
2730:
2700:
2603:
2439:
2329:
784:
421:
1862:"Plexxikon Announces First Patient Dosed in Phase 3 Trial of PLX4032 (RG7204) for Metastatic Melanoma"
1051:. After good results in 2014, the combination was submitted to the European Medical Agency and the US
6622:
6008:
4940:
4889:
2645:
2540:
2377:
2097:"FDA approves first treatment for certain patients with Erdheim–Chester disease, a rare blood cancer"
1693:
1576:
1519:
1448:
1350:
1208:
1160:
5758:
3833:
585:
37:
5763:
5177:
4874:
4066:
3498:
2765:
2755:
2575:
1337:
Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. (March 2010).
1136:
1101:
1090:
849:
823:
376:
249:
4799:
1664:
6381:
6294:
6239:
6193:
6138:
5873:
5813:
5441:
4814:
4744:
4303:
3901:
3843:
3794:
3153:
2795:
2785:
2770:
2690:
2238:
2017:
1849:
1831:
1669:
1278:
216:
6376:
6254:
6153:
5939:
5828:
5628:
5588:
5336:
5255:
5117:
5058:
5020:
4965:
4960:
4950:
4824:
4819:
4789:
4764:
4759:
4749:
4635:
4554:
4493:
4421:
4400:
4385:
4338:
3991:
936:
Vemurafenib only works in melanoma patients whose cancer has a V600E BRAF mutation (that is, at
6476:
6334:
6269:
6249:
6168:
6148:
5863:
5843:
5823:
5466:
4794:
4518:
4051:
3848:
551:
6299:
6289:
6244:
6198:
6188:
6143:
6068:
5967:
5934:
5914:
5878:
5868:
5818:
5778:
5250:
5230:
5197:
4980:
4829:
2830:
2318:
2281:
2182:
2156:
2009:
1788:
1709:
1602:
1545:
1474:
1417:
1368:
1319:
1296:
Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, et al. (May 2015).
1270:
1234:
1185:
1023:
840:
811:
541:
470:
338:
325:
313:
119:
6259:
6158:
6053:
5957:
5909:
5902:
5888:
5833:
5803:
5283:
5273:
5225:
5207:
4970:
4809:
4754:
6486:
5618:
2670:
2512:
2507:
2271:
2263:
2146:
2138:
2001:
1778:
1770:
1757:
Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. (August 2010).
1701:
1592:
1584:
1535:
1527:
1508:"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion"
1464:
1456:
1407:
1399:
1358:
1309:
1262:
1224:
1216:
956:
Three mechanisms of resistance to vemurafenib (covering 40% of cases) have been discovered:
930:
855:
625:
385:
55:
5010:
1506:
Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. (July 2012).
1123:
A trial combining vemurafenib and ipilimumab was stopped in April 2013 because of signs of
1043:
Further trials are planned including a trial of vemurafenib co-administered with GDC-0973 (
490:
6720:
6098:
2125:
Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, et al. (March 2018).
1565:"Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors"
1386:
Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, et al. (April 2010).
1197:"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma"
1684:
Garber K (December 2009). "Cancer research. Melanoma drug vindicates targeted approach".
2206:
1697:
1580:
1523:
1452:
1354:
1212:
612:
589:
6672:
6593:
6535:
6229:
6078:
6073:
5187:
5182:
3828:
3818:
3813:
3607:
3505:
3453:
3051:
2364:
2276:
2251:
2250:
Handa S, Lee JO, Derkach A, Stone RM, Saven A, Altman JK, et al. (December 2022).
2151:
2126:
1783:
1758:
1597:
1564:
1540:
1507:
1469:
1436:
1412:
1387:
1229:
1196:
1124:
1027:
1019:
1890:"Plexxikon and Roche Report Positive Data from Phase III BRAF Mutation Melanoma Study"
1865:
1848:
for "A Study of RO5185426 in
Previously Treated Patients With Metastatic Melanoma" at
1437:"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation"
28:
6730:
6366:
6279:
6208:
6178:
6113:
6023:
5977:
5853:
5783:
5728:
5717:
5202:
4910:
4593:
4498:
4390:
3664:
3554:
3516:
3493:
3425:
3420:
3410:
3186:
3182:
3170:
2977:
2760:
2725:
2545:
2525:
1403:
1195:
Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. (September 2010).
1048:
945:
601:
410:
161:
3760:
1563:
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. (July 2012).
1339:"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth"
1282:
6692:
6662:
6401:
6391:
6284:
6183:
6038:
5858:
5793:
5708:
5212:
5015:
4854:
4849:
4769:
4719:
4533:
4287:
4268:
4247:
4218:
3941:
3936:
3704:
3689:
3659:
3639:
3521:
3469:
3430:
3318:
3297:
3204:
3166:
3067:
3042:
3038:
2922:
2887:
2840:
2825:
2780:
2655:
2625:
2550:
2368:
2021:
978:
269:
264:
147:
2233:
1936:
1844:
1826:
1705:
1266:
6652:
6618:
6516:
6506:
6501:
6491:
6441:
6264:
6163:
5924:
5838:
5768:
5663:
5426:
5391:
5341:
5304:
5240:
5122:
5053:
5005:
4995:
4990:
4985:
4869:
4864:
4859:
4237:
4148:
4138:
4106:
4101:
4096:
4091:
4081:
4041:
4006:
3734:
3714:
3709:
3699:
3679:
3654:
3649:
3632:
3580:
3570:
3565:
3560:
3462:
3389:
3359:
3354:
3349:
3333:
3323:
3303:
3178:
3174:
3162:
3158:
3087:
2991:
2937:
2932:
2897:
2835:
2820:
2810:
2805:
2800:
2775:
2740:
2695:
2675:
2665:
2620:
2585:
2565:
2521:
2484:
2472:
2467:
2429:
2413:
2304:
2142:
1733:
2009 ASCO Annual
Meeting Abstract, J Clin Oncol 27:15s, 2009 (suppl; abstr 9000)
1642:
1435:
Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. (December 2010).
1044:
1034:
926:
899:
816:
155:
2308:
6471:
6436:
6431:
6421:
6411:
6329:
6118:
6093:
6083:
5929:
5883:
5743:
5569:
5538:
5507:
5476:
5421:
5396:
5376:
5361:
5351:
5245:
5162:
4955:
4935:
4834:
4779:
4774:
4598:
4503:
4488:
4283:
4242:
4214:
4183:
4143:
4046:
4001:
3996:
3971:
3966:
3956:
3869:
3863:
3853:
3749:
3744:
3719:
3684:
3669:
3644:
3627:
3617:
3575:
3546:
3511:
3477:
3394:
3384:
3364:
3328:
3313:
3308:
3278:
3212:
3208:
3190:
3138:
3117:
3077:
3072:
3011:
2942:
2917:
2892:
2815:
2750:
2710:
2705:
2685:
2680:
2660:
2650:
2640:
2555:
2535:
2517:
2425:
1063:
1059:
996:
937:
891:
792:
788:
670:
461:
2267:
2186:
6496:
6466:
6461:
6456:
6451:
6446:
6426:
6416:
6406:
6396:
6088:
6048:
5944:
5919:
5678:
5673:
5668:
5658:
5653:
5648:
5638:
5559:
5497:
5431:
5411:
5406:
5401:
5386:
5381:
5371:
5366:
5260:
5235:
5000:
4920:
4839:
4784:
4674:
4613:
4603:
4508:
4395:
4193:
4188:
4178:
4086:
4076:
4061:
4036:
4031:
4021:
4016:
4011:
3739:
3729:
3724:
3694:
3674:
3622:
3612:
3600:
3595:
3541:
3536:
3482:
3415:
3288:
3283:
3268:
3263:
3258:
3248:
3243:
3238:
3143:
3133:
3112:
3107:
3102:
3097:
3092:
3082:
3062:
3026:
3021:
3016:
3006:
3001:
2968:
2963:
2958:
2927:
2907:
2902:
2745:
2735:
2560:
2408:
1908:"Vemurafenib Improves Overall Survival in Patients with Metastatic Melanoma"
1093:
approved vemurafenib as a monotherapy for the treatment of adults with BRAF
1058:
In
January 2015, trial results compared vemurafenib with the combination of
918:
906:
141:
20:
2322:
2285:
2160:
2013:
1792:
1713:
1606:
1549:
1478:
1421:
1372:
1323:
1274:
1238:
1774:
1314:
1297:
6667:
6386:
6043:
5643:
5633:
5613:
5548:
5517:
5486:
5450:
5356:
5346:
4693:
4173:
4116:
4026:
3986:
3489:
3253:
3057:
2996:
2952:
2912:
2882:
2635:
2499:
2495:
2420:
1097:
968:
922:
895:
804:
441:
1588:
1531:
1460:
1363:
1338:
1298:"Metastatic melanoma - a review of current and future treatment options"
1220:
450:
6642:
6063:
5528:
4930:
3891:
2593:
864:
396:
1189:
6555:
6219:
6108:
6033:
5738:
5733:
5157:
5152:
5106:
5102:
5098:
5094:
5090:
5086:
5082:
4734:
4273:
3951:
961:
941:
902:
521:
2005:
367:-(3-{pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide
510:
6587:
6583:
6579:
6575:
6571:
6567:
6563:
6559:
6274:
6173:
5848:
5788:
5602:
5325:
5321:
5317:
5313:
4804:
4668:
4587:
4583:
4482:
4478:
4474:
4470:
4379:
4375:
4226:
3473:
3199:
3033:
2982:
2462:
1094:
693:
684:
557:
1958:"MEK/BRAF Inhibitor Combo Reduces Death by One-Third in Melanoma"
1487:"Researchers Uncover Drug-Resistance Mechanisms in BRAF Melanoma"
6058:
4664:
4660:
4656:
4652:
4648:
4644:
4579:
4575:
4571:
4567:
4563:
4466:
4462:
4454:
4450:
4446:
4442:
4438:
4434:
4430:
4371:
4367:
4363:
4359:
4355:
4351:
4347:
4299:
4295:
4291:
4257:
4222:
4203:
3588:
3374:
2872:
2598:
2580:
2570:
2530:
2398:
501:
319:
187:
178:
3764:
2333:
1830:
for "Safety Study of PLX4032 in
Patients With Solid Tumors" at
1621:"BRIM-2 Upholds Benefits Emerging with Vemurafenib in Melanoma"
779:
332:
195:
1759:"Inhibition of mutated, activated BRAF in metastatic melanoma"
1086:
Vemurafenib was approved for use in Canada in
February 2012.
2307:. In Pratt VM, McLeod HL, Rubinstein WS, et al. (eds.).
1111:(FDA) approved vemurafenib for the treatment of people with
574:
295:
227:
85:
70:
64:
716:
CCCS(=O)(=O)Nc1ccc(F)c(c1F)C(=O)c2cc3c2cc(cn3)c4ccc(Cl)cc4
1161:"Australian Product Information: Zelboraf® (vemurafenib)"
91:
79:
308:
975:
mutates, reactivating the normal BRAF survival pathway.
960:
Cancer cells begin to overexpress cell surface protein
753:
6658:
Pituitary adenylate cyclase-activating peptide (PACAP)
1864:(Press release). Plexxikon. 2010-01-08. Archived from
6704:
940:
position number 600 on the B-Raf protein, the normal
103:
88:
82:
58:
94:
76:
61:
6525:
6312:
6207:
5976:
5716:
5707:
5687:
5601:
5578:
5547:
5516:
5485:
5449:
5440:
5292:
5135:
5068:
5030:
4897:
4888:
4706:
4683:
4623:
4542:
4409:
4326:
4317:
4256:
4202:
4115:
3919:
3910:
3879:
3801:
3445:
3222:
2863:
2853:
2613:
2494:
2454:
2389:
2376:
863:
839:
834:
822:
810:
800:
765:
682:
669:
624:
619:
600:
568:
540:
520:
500:
480:
460:
440:
429:
420:
395:
375:
347:
285:
280:
255:
241:
215:
168:
154:
136:
128:
118:
73:
67:
49:
44:
6604:Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)
5462:Glial cell line-derived neurotrophic factor (GDNF)
5115:Cleavage products/derivatives with unknown target:
2073:. The International Cancer Network. Archived from
6638:Macrophage-stimulating protein (MSP; HLP, HGFLP)
2305:"Vemurafenib Therapy and BRAF and NRAS Genotype"
409:
4279:Heparin-binding EGF-like growth factor (HB-EGF)
3962:Heparin-binding EGF-like growth factor (HB-EGF)
384:
2237:for "Hairy Cell Leukemia with Vemurafebib" at
1180:
1178:
1176:
1174:
1030:study (for metastatic melanoma) were ongoing.
933:− if the B-Raf has the common V600E mutation.
200:
6690:Additional growth factor receptor modulators:
3776:
2345:
2315:National Center for Biotechnology Information
1155:
1153:
8:
5044:Insulin-like growth factor-2 (somatomedin A)
4926:Insulin-like growth factor-2 (somatomedin A)
4916:Insulin-like growth factor-1 (somatomedin C)
2207:"Hairy Cell Leukemia: Celebrating Progress?"
1894:Genetic Engineering & Biotechnology News
1491:Genetic Engineering & Biotechnology News
1115:(ECD), a rare type of histiocytic neoplasm.
19:
1896:. Mary Ann Liebert Publishers. 6 June 2011.
1104:, the most aggressive form of skin cancer.
964:, creating an alternative survival pathway.
5713:
5446:
4894:
4323:
3916:
3783:
3769:
3761:
2860:
2386:
2352:
2338:
2330:
1884:
1882:
778:
611:
588:
469:
6737:Antineoplastic and immunomodulating drugs
2275:
2150:
1802:"PLX4032: The Good News and the Bad News"
1782:
1596:
1539:
1468:
1411:
1362:
1313:
1228:
489:
6648:Migration-stimulating factor (MSF; PRG4)
6711:
3977:Transforming growth factor alpha (TGFα)
1149:
925:cell lines. Vemurafenib interrupts the
733:
713:
584:
449:
361:
160:
6551:Connective tissue growth factor (CTGF)
762:
602:
18:
6614:Hepatoma-derived growth factor (HDGF)
894:used for the treatment of late-stage
550:
529:
146:
7:
6782:Drugs developed by Hoffmann-La Roche
1392:Pigment Cell & Melanoma Research
556:
268:
1763:The New England Journal of Medicine
1665:"A Roller Coaster Chase for a Cure"
1022:trial for solid tumors (including
509:
400:
132:PLX4032, RG7204, PLX4720, RO5185426
14:
2036:"Notice of Decision for ZELBORAF"
1643:"Drug hope for advanced melanoma"
6714:
6633:Leukemia inhibitory factor (LIF)
1404:10.1111/j.1755-148X.2010.00685.x
651:
645:
642:
636:
54:
36:
27:
5801:Negative allosteric modulators:
2065:Hofland P (February 20, 2012).
2042:. 11 March 2012. Archived from
741:Key:GPXBXXGIAQBQNI-UHFFFAOYSA-N
6119:Gossypetin (3,5,7,8,3',4'-HHF)
5310:Platelet-derived growth factor
1994:Nature Reviews. Drug Discovery
663:
657:
630:
1:
6325:Placental growth factor (PGF)
1933:"Cobimetinib at exelixis.com"
1706:10.1126/science.326.5960.1619
1267:10.1158/1541-7786.MCR-07-2001
1083:to gain regulatory approval.
1081:fragment-based lead discovery
886:), sold under the brand name
6787:Drugs developed by Genentech
6609:Glia maturation factor (GMF)
5118:Glypromate (GPE, (1-3)IGF-1)
2175:"Getting close and personal"
2103:Food and Drug Administration
1800:Lowe D (September 9, 2010).
1131:Treating Hairy Cell Leukemia
1109:Food and Drug Administration
1053:Food and Drug Administration
898:. It is an inhibitor of the
2143:10.1001/jamaoncol.2017.5029
1625:Oncology & Biotech News
787:of B-Raf (rainbow colored,
6813:
6541:Colony-stimulating factors
6533:Additional growth factors:
2855:Tyrosine kinase inhibitors
2325:. Bookshelf ID: NBK447416.
2310:Medical Genetics Summaries
1974:(Press release). Genentech
1302:Acta Dermato-Venereologica
1165:Roche Products Pty Limited
1135:In 2012, a grant from the
785:Crystallographic structure
620:Chemical and physical data
5889:SNA-120 (pegylated K252a)
5061:(against IGF-1 and IGF-2)
5023:(against IGF-1 and IGF-2)
2721:Mirvetuximab soravtansine
1255:Molecular Cancer Research
1107:In November 2017, the US
1100:positive unresectable or
1066:for metastatic melanoma.
777:
770:
749:
724:
704:
352:
35:
26:
6747:4-Chlorophenyl compounds
4725:Hepatocyte growth factor
4284:Neuregulins (heregulins)
4215:Neuregulins (heregulins)
4159:Trastuzumab duocarmazine
3872:(against angiopoietin 2)
3866:(against angiopoietin 3)
2865:Receptor tyrosine kinase
2391:Receptor tyrosine kinase
2268:10.1182/blood.2022016183
1055:for marketing approval.
983:hepatocyte growth factor
829:protein kinase inhibitor
4072:Depatuxizumab mafodotin
2455:Others for solid tumors
2361:Targeted cancer therapy
1663:Harmon A (2010-02-21).
1113:Erdheim–Chester disease
6695:(neurotrophin mixture)
6683:Wnt signaling proteins
6364:Allosteric modulators:
6084:Norwogonin (5,7,8-THF)
4304:5 (tomoregulin, TMEFF)
4154:Trastuzumab deruxtecan
3792:Growth factor receptor
2716:Loncastuximab tesirine
2445:Trastuzumab deruxtecan
2231:Clinical trial number
1842:Clinical trial number
1824:Clinical trial number
1645:. BBC News. 2009-06-02
1089:In February 2012, the
1033:A phase III trial (vs
1010:phase I clinical study
6623:T-cell growth factors
4880:Telisotuzumab vedotin
4164:Trastuzumab emtansine
2791:Sacituzumab govitecan
2731:Moxetumomab pasudotox
2701:Inotuzumab ozogamicin
2604:Gemtuzumab ozogamicin
2440:Trastuzumab emtansine
2381:monoclonal antibodies
2365:antineoplastic agents
1775:10.1056/NEJMoa1002011
1315:10.2340/00015555-2035
931:B-Raf/MEK/ERK pathway
919:programmed cell death
905:and was developed by
5208:EVT-901 (SAR-127963)
4941:Mecasermin rinfabate
2646:Belantamab mafodotin
1493:. November 25, 2010.
16:Targeted cancer drug
3499:Denileukin diftitox
3161:(ALK, ROS1, NTRK),
2766:Polatuzumab vedotin
2756:Oportuzumab monatox
2181:. January 4, 2014.
1804:. In the Pipeline.
1698:2009Sci...326.1619G
1589:10.1038/nature11249
1581:2012Natur.487..505W
1532:10.1038/nature11183
1524:2012Natur.487..500S
1461:10.1038/nature09626
1453:2010Natur.468..973N
1364:10.1038/nature08833
1355:2010Natur.464..431H
1221:10.1038/nature09454
1213:2010Natur.467..596B
1137:Hairy cell leukemia
1102:metastatic melanoma
1091:European Commission
1070:Society and culture
917:Vemurafenib causes
913:Mechanism of action
824:Mechanism of action
328:(Prescription only)
304:(Prescription only)
23:
6374:Kinase inhibitors:
6237:Kinase inhibitors:
6136:Kinase inhibitors:
5811:Kinase inhibitors:
5626:Kinase inhibitors:
5586:Kinase inhibitors:
5567:Kinase inhibitors:
5536:Kinase inhibitors:
5505:Kinase inhibitors:
5474:Kinase inhibitors:
5334:Kinase inhibitors:
4948:Kinase inhibitors:
4742:Kinase inhibitors:
4531:Kinase inhibitors:
4524:Aprutumab ixadotin
4171:Kinase inhibitors:
3984:Kinase inhibitors:
3841:Kinase inhibitors:
3185:(ROS1, TRK, ALK),
2691:Enfortumab vedotin
2239:ClinicalTrials.gov
1850:ClinicalTrials.gov
1832:ClinicalTrials.gov
1670:The New York Times
6757:CYP2D6 inhibitors
6752:CYP1A2 inhibitors
6702:
6701:
6308:
6307:
6069:N-Acetylserotonin
5968:ReN-1820 (TrkAd5)
5597:
5596:
5131:
5130:
5076:Binding proteins:
4735:Dihexa (PNB-0408)
4702:
4701:
4313:
4312:
4227:6 (neuroglycan C)
3947:EGF (urogastrone)
3925:
3758:
3757:
3441:
3440:
2849:
2848:
2831:Tisotumab vedotin
2262:(25): 2663–2671.
2077:on April 11, 2012
1575:(7408): 505–509.
1518:(7408): 500–504.
1447:(7326): 973–977.
1349:(7287): 431–435.
1207:(7315): 596–599.
1024:colorectal cancer
877:
876:
859:
812:Biological target
761:
760:
695:Interactive image
570:CompTox Dashboard
336:
323:
311:
299:
231:
198:
181:
6804:
6742:B-Raf inhibitors
6719:
6718:
6717:
6710:
6514:Decoy receptors:
6487:Alacizumab pegol
5965:Decoy receptors:
5714:
5619:Stem cell factor
5560:Persephin (PSPN)
5498:Neurturin (NRTN)
5447:
5284:LEVI-04 (p75-Fc)
5281:Decoy receptors:
4895:
4324:
3923:
3917:
3785:
3778:
3771:
3762:
3472:peptide against
3045:(AXL, ALK, LTK))
2861:
2671:Dinutuximab beta
2387:
2354:
2347:
2340:
2331:
2326:
2290:
2289:
2279:
2247:
2241:
2229:
2223:
2222:
2220:
2218:
2203:
2197:
2196:
2194:
2193:
2171:
2165:
2164:
2154:
2122:
2116:
2115:
2113:
2112:
2093:
2087:
2086:
2084:
2082:
2062:
2056:
2055:
2053:
2051:
2032:
2026:
2025:
1989:
1983:
1982:
1980:
1979:
1968:
1962:
1961:
1954:
1948:
1947:
1945:
1944:
1935:. Archived from
1929:
1923:
1922:
1920:
1919:
1910:. Archived from
1904:
1898:
1897:
1886:
1877:
1876:
1874:
1873:
1858:
1852:
1840:
1834:
1822:
1816:
1813:
1808:. Archived from
1796:
1786:
1754:
1748:
1747:
1745:
1744:
1735:. Archived from
1724:
1718:
1717:
1681:
1675:
1674:
1660:
1654:
1653:
1651:
1650:
1639:
1633:
1632:
1617:
1611:
1610:
1600:
1560:
1554:
1553:
1543:
1503:
1497:
1494:
1482:
1472:
1432:
1426:
1425:
1415:
1383:
1377:
1376:
1366:
1334:
1328:
1327:
1317:
1293:
1287:
1286:
1249:
1243:
1242:
1232:
1192:
1182:
1169:
1168:
1167:. 25 March 2020.
1157:
1018:In early 2010 a
873:
858:
852:
847:
782:
763:
757:
756:
697:
677:
665:
659:
653:
647:
644:
638:
632:
615:
604:
593:
592:
578:
576:
560:
554:
533:
513:
493:
473:
453:
433:
413:
403:
402:
388:
334:
331:
321:
318:
310:
307:
297:
294:
272:
229:
226:
208:
197:
194:
191:
180:
177:
164:
150:
110:
106:
101:
100:
97:
96:
93:
90:
87:
84:
81:
78:
75:
72:
69:
66:
63:
60:
40:
31:
24:
22:
6812:
6811:
6807:
6806:
6805:
6803:
6802:
6801:
6762:CYP3A4 inducers
6727:
6726:
6725:
6715:
6713:
6705:
6703:
6698:
6643:Midkine (NEGF2)
6521:
6304:
6203:
5972:
5910:ABT-110 (PG110)
5703:
5683:
5593:
5574:
5543:
5512:
5481:
5436:
5288:
5226:ABT-110 (PG110)
5127:
5064:
5026:
4884:
4698:
4679:
4619:
4616:(against FGF23)
4538:
4405:
4309:
4252:
4198:
4111:
3922:
3906:
3875:
3797:
3789:
3759:
3754:
3608:Pi3K inhibitors
3506:mTOR inhibitors
3437:
3218:
3189:(VEGFR, FGFR),
2845:
2609:
2490:
2450:
2372:
2358:
2303:Dean L (2017).
2302:
2299:
2297:Further reading
2294:
2293:
2249:
2248:
2244:
2230:
2226:
2216:
2214:
2213:. July 29, 2022
2205:
2204:
2200:
2191:
2189:
2173:
2172:
2168:
2124:
2123:
2119:
2110:
2108:
2107:(Press release)
2095:
2094:
2090:
2080:
2078:
2064:
2063:
2059:
2049:
2047:
2034:
2033:
2029:
2006:10.1038/nrd3847
2000:(11): 873–886.
1991:
1990:
1986:
1977:
1975:
1970:
1969:
1965:
1956:
1955:
1951:
1942:
1940:
1931:
1930:
1926:
1917:
1915:
1906:
1905:
1901:
1888:
1887:
1880:
1871:
1869:
1860:
1859:
1855:
1841:
1837:
1823:
1819:
1799:
1756:
1755:
1751:
1742:
1740:
1726:
1725:
1721:
1683:
1682:
1678:
1662:
1661:
1657:
1648:
1646:
1641:
1640:
1636:
1631:(7). July 2011.
1619:
1618:
1614:
1562:
1561:
1557:
1505:
1504:
1500:
1485:
1434:
1433:
1429:
1385:
1384:
1380:
1336:
1335:
1331:
1295:
1294:
1290:
1251:
1250:
1246:
1194:
1184:
1183:
1172:
1159:
1158:
1151:
1146:
1133:
1121:
1077:
1072:
1006:
992:
954:
944:is replaced by
915:
869:
854:
848:
801:Therapeutic use
796:
752:
750:
745:
742:
737:
732:
731:
720:
717:
712:
711:
700:
675:
662:
656:
650:
641:
635:
596:
572:
564:
536:
516:
496:
476:
456:
436:
416:
399:
391:
371:
368:
360:
359:
343:
276:
244:
237:
218:
211:
108:
104:
57:
53:
17:
12:
11:
5:
6810:
6808:
6800:
6799:
6794:
6792:Daiichi Sankyo
6789:
6784:
6779:
6774:
6769:
6764:
6759:
6754:
6749:
6744:
6739:
6729:
6728:
6724:
6723:
6700:
6699:
6697:
6696:
6686:
6685:
6680:
6673:Thrombopoietin
6670:
6665:
6660:
6655:
6650:
6645:
6640:
6635:
6630:
6616:
6611:
6606:
6601:
6594:Erythropoietin
6591:
6553:
6548:
6538:
6536:Adrenomedullin
6529:
6527:
6523:
6522:
6520:
6519:
6510:
6509:
6504:
6499:
6494:
6489:
6480:
6479:
6474:
6469:
6464:
6459:
6454:
6449:
6444:
6439:
6434:
6429:
6424:
6419:
6414:
6409:
6404:
6399:
6394:
6389:
6384:
6379:
6370:
6369:
6360:
6359:
6337:
6332:
6327:
6318:
6316:
6310:
6309:
6306:
6305:
6303:
6302:
6297:
6292:
6287:
6282:
6277:
6272:
6267:
6262:
6257:
6252:
6247:
6242:
6233:
6232:
6227:
6222:
6213:
6211:
6205:
6204:
6202:
6201:
6196:
6191:
6186:
6181:
6176:
6171:
6166:
6161:
6156:
6151:
6146:
6141:
6132:
6131:
6122:
6121:
6116:
6111:
6102:
6101:
6096:
6091:
6086:
6081:
6076:
6071:
6066:
6061:
6056:
6051:
6046:
6041:
6036:
6031:
6026:
6021:
6016:
6011:
6006:
6001:
5999:4'-DMA-7,8-DHF
5996:
5991:
5982:
5980:
5974:
5973:
5971:
5970:
5961:
5960:
5948:
5947:
5942:
5937:
5932:
5927:
5922:
5917:
5912:
5893:
5892:
5886:
5881:
5876:
5871:
5866:
5861:
5856:
5851:
5846:
5841:
5836:
5831:
5826:
5821:
5816:
5807:
5806:
5797:
5796:
5791:
5786:
5781:
5772:
5771:
5766:
5761:
5759:Gambogic amide
5756:
5751:
5746:
5741:
5736:
5731:
5722:
5720:
5711:
5705:
5704:
5702:
5701:
5693:
5691:
5685:
5684:
5682:
5681:
5676:
5671:
5666:
5661:
5656:
5651:
5646:
5641:
5636:
5631:
5622:
5621:
5616:
5607:
5605:
5599:
5598:
5595:
5594:
5592:
5591:
5582:
5580:
5576:
5575:
5573:
5572:
5563:
5562:
5553:
5551:
5545:
5544:
5542:
5541:
5532:
5531:
5529:Artemin (ARTN)
5522:
5520:
5514:
5513:
5511:
5510:
5501:
5500:
5491:
5489:
5483:
5482:
5480:
5479:
5470:
5469:
5464:
5455:
5453:
5444:
5438:
5437:
5435:
5434:
5429:
5424:
5415:
5414:
5409:
5404:
5399:
5394:
5389:
5384:
5379:
5374:
5369:
5364:
5359:
5354:
5349:
5344:
5339:
5330:
5329:
5307:
5298:
5296:
5290:
5289:
5287:
5286:
5277:
5276:
5264:
5263:
5258:
5253:
5248:
5243:
5238:
5233:
5228:
5216:
5215:
5210:
5205:
5200:
5191:
5190:
5185:
5180:
5175:
5170:
5165:
5160:
5155:
5150:
5141:
5139:
5133:
5132:
5129:
5128:
5126:
5125:
5120:
5111:
5110:
5072:
5070:
5066:
5065:
5063:
5062:
5056:
5047:
5046:
5036:
5034:
5028:
5027:
5025:
5024:
5018:
5013:
5008:
5003:
4998:
4993:
4988:
4983:
4974:
4973:
4968:
4963:
4958:
4953:
4944:
4943:
4938:
4933:
4928:
4923:
4918:
4913:
4903:
4901:
4892:
4886:
4885:
4883:
4882:
4877:
4872:
4867:
4862:
4857:
4852:
4843:
4842:
4837:
4832:
4827:
4822:
4817:
4812:
4807:
4802:
4797:
4792:
4787:
4782:
4777:
4772:
4767:
4762:
4757:
4752:
4747:
4738:
4737:
4728:
4727:
4722:
4712:
4710:
4704:
4703:
4700:
4699:
4697:
4696:
4687:
4685:
4681:
4680:
4678:
4677:
4672:
4638:
4629:
4627:
4621:
4620:
4618:
4617:
4607:
4606:
4601:
4596:
4591:
4557:
4548:
4546:
4540:
4539:
4537:
4536:
4527:
4526:
4521:
4512:
4511:
4506:
4501:
4496:
4491:
4486:
4424:
4415:
4413:
4407:
4406:
4404:
4403:
4398:
4393:
4388:
4383:
4341:
4332:
4330:
4321:
4315:
4314:
4311:
4310:
4308:
4307:
4281:
4276:
4271:
4262:
4260:
4254:
4253:
4251:
4250:
4245:
4240:
4231:
4230:
4208:
4206:
4200:
4199:
4197:
4196:
4191:
4186:
4181:
4176:
4167:
4166:
4161:
4156:
4151:
4146:
4141:
4132:
4131:
4121:
4119:
4113:
4112:
4110:
4109:
4104:
4099:
4094:
4089:
4084:
4079:
4074:
4069:
4064:
4055:
4054:
4049:
4044:
4039:
4034:
4029:
4024:
4019:
4014:
4009:
4004:
3999:
3994:
3989:
3980:
3979:
3974:
3969:
3964:
3959:
3954:
3949:
3944:
3939:
3929:
3927:
3914:
3908:
3907:
3905:
3904:
3899:
3894:
3885:
3883:
3877:
3876:
3874:
3873:
3867:
3857:
3856:
3851:
3846:
3837:
3836:
3834:Angiopoietin 3
3831:
3829:Angiopoietin 2
3822:
3821:
3819:Angiopoietin 4
3816:
3814:Angiopoietin 1
3807:
3805:
3799:
3798:
3790:
3788:
3787:
3780:
3773:
3765:
3756:
3755:
3753:
3752:
3747:
3742:
3737:
3732:
3727:
3722:
3717:
3712:
3707:
3702:
3697:
3692:
3687:
3682:
3677:
3672:
3667:
3662:
3657:
3652:
3647:
3642:
3637:
3636:
3635:
3630:
3625:
3620:
3615:
3605:
3604:
3603:
3598:
3585:
3584:
3583:
3578:
3573:
3568:
3563:
3555:CDK inhibitors
3551:
3550:
3549:
3544:
3539:
3526:
3525:
3524:
3519:
3514:
3502:
3486:
3466:
3454:fusion protein
3449:
3447:
3443:
3442:
3439:
3438:
3436:
3435:
3434:
3433:
3428:
3423:
3418:
3413:
3400:
3399:
3398:
3397:
3392:
3387:
3370:
3369:
3368:
3367:
3362:
3357:
3352:
3339:
3338:
3337:
3336:
3331:
3326:
3321:
3316:
3311:
3306:
3293:
3292:
3286:
3274:
3273:
3272:
3271:
3266:
3261:
3256:
3251:
3246:
3241:
3228:
3226:
3220:
3219:
3217:
3216:
3195:
3194:
3193:(VEGFR, EGFR).
3149:
3148:
3147:
3146:
3141:
3136:
3123:
3122:
3121:
3120:
3115:
3110:
3105:
3100:
3095:
3090:
3085:
3080:
3075:
3070:
3065:
3060:
3047:
3046:
3030:
3024:
3019:
3014:
3009:
3004:
2999:
2994:
2974:
2973:
2972:
2971:
2966:
2961:
2951:HER1/EGFR and
2947:
2946:
2940:
2935:
2930:
2925:
2920:
2915:
2910:
2905:
2900:
2895:
2890:
2885:
2869:
2867:
2858:
2851:
2850:
2847:
2846:
2844:
2843:
2838:
2833:
2828:
2823:
2818:
2813:
2808:
2803:
2798:
2793:
2788:
2783:
2778:
2773:
2768:
2763:
2758:
2753:
2748:
2743:
2738:
2733:
2728:
2723:
2718:
2713:
2708:
2703:
2698:
2693:
2688:
2683:
2678:
2673:
2668:
2663:
2658:
2653:
2648:
2643:
2638:
2633:
2630:+hyaluronidase
2623:
2617:
2615:
2611:
2610:
2608:
2607:
2590:
2589:
2563:
2558:
2553:
2548:
2543:
2538:
2504:
2502:
2492:
2491:
2489:
2488:
2476:
2470:
2458:
2456:
2452:
2451:
2449:
2448:
2442:
2437:
2434:+hyaluronidase
2417:
2411:
2395:
2393:
2384:
2374:
2373:
2359:
2357:
2356:
2349:
2342:
2334:
2328:
2327:
2298:
2295:
2292:
2291:
2242:
2224:
2198:
2166:
2137:(3): 384–388.
2117:
2088:
2057:
2027:
1984:
1963:
1949:
1924:
1899:
1878:
1853:
1835:
1817:
1815:
1814:
1812:on 2010-09-11.
1769:(9): 809–819.
1749:
1719:
1692:(5960): 1619.
1676:
1655:
1634:
1612:
1555:
1498:
1496:
1495:
1427:
1398:(2): 190–200.
1378:
1329:
1308:(5): 516–524.
1288:
1261:(5): 751–759.
1244:
1170:
1148:
1147:
1145:
1142:
1132:
1129:
1125:liver toxicity
1120:
1117:
1076:
1073:
1071:
1068:
1005:
1002:
991:
988:
987:
986:
976:
965:
953:
950:
927:B-Raf/MEK step
914:
911:
875:
874:
867:
861:
860:
844:
837:
836:
835:External links
832:
831:
826:
820:
819:
814:
808:
807:
802:
798:
797:
783:
775:
774:
772:Drug mechanism
768:
767:
759:
758:
747:
746:
744:
743:
740:
738:
735:
727:
726:
725:
722:
721:
719:
718:
715:
707:
706:
705:
702:
701:
699:
698:
690:
688:
680:
679:
673:
667:
666:
660:
654:
648:
639:
633:
628:
622:
621:
617:
616:
606:
598:
597:
595:
594:
586:DTXSID50238710
581:
579:
566:
565:
563:
562:
546:
544:
538:
537:
535:
534:
526:
524:
518:
517:
515:
514:
506:
504:
498:
497:
495:
494:
486:
484:
478:
477:
475:
474:
466:
464:
458:
457:
455:
454:
446:
444:
438:
437:
435:
434:
426:
424:
418:
417:
415:
414:
406:
404:
393:
392:
390:
389:
381:
379:
373:
372:
370:
369:
363:
355:
354:
353:
350:
349:
345:
344:
342:
341:
329:
316:
305:
291:
289:
283:
282:
278:
277:
275:
274:
261:
259:
253:
252:
247:
245:administration
239:
238:
236:
235:
233:
223:
221:
213:
212:
210:
209:
192:
174:
172:
166:
165:
158:
152:
151:
144:
134:
133:
130:
126:
125:
122:
116:
115:
51:
47:
46:
42:
41:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
6809:
6798:
6797:Diarylketones
6795:
6793:
6790:
6788:
6785:
6783:
6780:
6778:
6775:
6773:
6770:
6768:
6765:
6763:
6760:
6758:
6755:
6753:
6750:
6748:
6745:
6743:
6740:
6738:
6735:
6734:
6732:
6722:
6712:
6708:
6694:
6691:
6688:
6687:
6684:
6681:
6678:
6674:
6671:
6669:
6666:
6664:
6661:
6659:
6656:
6654:
6651:
6649:
6646:
6644:
6641:
6639:
6636:
6634:
6631:
6628:
6624:
6620:
6617:
6615:
6612:
6610:
6607:
6605:
6602:
6599:
6595:
6592:
6589:
6585:
6581:
6577:
6573:
6569:
6565:
6561:
6557:
6554:
6552:
6549:
6546:
6542:
6539:
6537:
6534:
6531:
6530:
6528:
6524:
6518:
6515:
6512:
6511:
6508:
6505:
6503:
6500:
6498:
6495:
6493:
6490:
6488:
6485:
6482:
6481:
6478:
6475:
6473:
6470:
6468:
6465:
6463:
6460:
6458:
6455:
6453:
6450:
6448:
6445:
6443:
6440:
6438:
6435:
6433:
6430:
6428:
6425:
6423:
6420:
6418:
6415:
6413:
6410:
6408:
6405:
6403:
6400:
6398:
6395:
6393:
6390:
6388:
6385:
6383:
6380:
6378:
6375:
6372:
6371:
6368:
6367:Cyclotraxin B
6365:
6362:
6361:
6357:
6353:
6349:
6345:
6341:
6338:
6336:
6333:
6331:
6328:
6326:
6323:
6320:
6319:
6317:
6315:
6311:
6301:
6298:
6296:
6293:
6291:
6288:
6286:
6283:
6281:
6280:Larotrectinib
6278:
6276:
6273:
6271:
6268:
6266:
6263:
6261:
6258:
6256:
6253:
6251:
6248:
6246:
6243:
6241:
6238:
6235:
6234:
6231:
6228:
6226:
6223:
6221:
6218:
6215:
6214:
6212:
6210:
6206:
6200:
6197:
6195:
6192:
6190:
6187:
6185:
6182:
6180:
6179:Larotrectinib
6177:
6175:
6172:
6170:
6167:
6165:
6162:
6160:
6157:
6155:
6152:
6150:
6147:
6145:
6142:
6140:
6137:
6134:
6133:
6130:
6127:
6124:
6123:
6120:
6117:
6115:
6114:Cyclotraxin B
6112:
6110:
6107:
6104:
6103:
6100:
6097:
6095:
6092:
6090:
6087:
6085:
6082:
6080:
6077:
6075:
6072:
6070:
6067:
6065:
6062:
6060:
6057:
6055:
6052:
6050:
6047:
6045:
6042:
6040:
6037:
6035:
6032:
6030:
6027:
6025:
6024:Amitriptyline
6022:
6020:
6017:
6015:
6012:
6010:
6007:
6005:
6002:
6000:
5997:
5995:
5992:
5990:
5987:
5984:
5983:
5981:
5979:
5975:
5969:
5966:
5963:
5962:
5959:
5956:
5953:
5950:
5949:
5946:
5943:
5941:
5938:
5936:
5933:
5931:
5928:
5926:
5923:
5921:
5918:
5916:
5913:
5911:
5908:
5904:
5901:
5900:Against TrkA:
5898:
5895:
5894:
5890:
5887:
5885:
5882:
5880:
5877:
5875:
5872:
5870:
5867:
5865:
5862:
5860:
5857:
5855:
5854:Larotrectinib
5852:
5850:
5847:
5845:
5842:
5840:
5837:
5835:
5832:
5830:
5827:
5825:
5822:
5820:
5817:
5815:
5812:
5809:
5808:
5805:
5802:
5799:
5798:
5795:
5792:
5790:
5787:
5785:
5784:Dexamethasone
5782:
5780:
5777:
5774:
5773:
5770:
5767:
5765:
5762:
5760:
5757:
5755:
5752:
5750:
5747:
5745:
5742:
5740:
5737:
5735:
5732:
5730:
5729:Amitriptyline
5727:
5724:
5723:
5721:
5719:
5715:
5712:
5710:
5706:
5699:
5695:
5694:
5692:
5690:
5686:
5680:
5677:
5675:
5672:
5670:
5667:
5665:
5662:
5660:
5657:
5655:
5652:
5650:
5647:
5645:
5642:
5640:
5637:
5635:
5632:
5630:
5627:
5624:
5623:
5620:
5617:
5615:
5612:
5609:
5608:
5606:
5604:
5600:
5590:
5587:
5584:
5583:
5581:
5577:
5571:
5568:
5565:
5564:
5561:
5558:
5555:
5554:
5552:
5550:
5546:
5540:
5537:
5534:
5533:
5530:
5527:
5524:
5523:
5521:
5519:
5515:
5509:
5506:
5503:
5502:
5499:
5496:
5493:
5492:
5490:
5488:
5484:
5478:
5475:
5472:
5471:
5468:
5465:
5463:
5460:
5457:
5456:
5454:
5452:
5448:
5445:
5443:
5439:
5433:
5430:
5428:
5425:
5423:
5420:
5417:
5416:
5413:
5410:
5408:
5405:
5403:
5400:
5398:
5395:
5393:
5390:
5388:
5385:
5383:
5380:
5378:
5375:
5373:
5370:
5368:
5365:
5363:
5360:
5358:
5355:
5353:
5350:
5348:
5345:
5343:
5340:
5338:
5335:
5332:
5331:
5327:
5323:
5319:
5315:
5311:
5308:
5306:
5303:
5300:
5299:
5297:
5295:
5291:
5285:
5282:
5279:
5278:
5275:
5272:
5269:
5266:
5265:
5262:
5259:
5257:
5254:
5252:
5249:
5247:
5244:
5242:
5239:
5237:
5234:
5232:
5229:
5227:
5224:
5221:
5218:
5217:
5214:
5211:
5209:
5206:
5204:
5203:Dexamethasone
5201:
5199:
5196:
5193:
5192:
5189:
5186:
5184:
5181:
5179:
5176:
5174:
5171:
5169:
5166:
5164:
5161:
5159:
5156:
5154:
5151:
5149:
5146:
5143:
5142:
5140:
5138:
5134:
5124:
5121:
5119:
5116:
5113:
5112:
5108:
5104:
5100:
5096:
5092:
5088:
5084:
5080:
5077:
5074:
5073:
5071:
5067:
5060:
5057:
5055:
5052:
5049:
5048:
5045:
5041:
5038:
5037:
5035:
5033:
5029:
5022:
5019:
5017:
5014:
5012:
5009:
5007:
5004:
5002:
4999:
4997:
4994:
4992:
4989:
4987:
4984:
4982:
4979:
4976:
4975:
4972:
4969:
4967:
4964:
4962:
4959:
4957:
4954:
4952:
4949:
4946:
4945:
4942:
4939:
4937:
4934:
4932:
4929:
4927:
4924:
4922:
4919:
4917:
4914:
4912:
4911:des(1-3)IGF-1
4908:
4905:
4904:
4902:
4900:
4896:
4893:
4891:
4887:
4881:
4878:
4876:
4875:Telisotuzumab
4873:
4871:
4868:
4866:
4863:
4861:
4858:
4856:
4853:
4851:
4848:
4845:
4844:
4841:
4838:
4836:
4833:
4831:
4828:
4826:
4823:
4821:
4818:
4816:
4813:
4811:
4808:
4806:
4803:
4801:
4798:
4796:
4793:
4791:
4788:
4786:
4783:
4781:
4778:
4776:
4773:
4771:
4768:
4766:
4763:
4761:
4758:
4756:
4753:
4751:
4748:
4746:
4743:
4740:
4739:
4736:
4733:
4732:Potentiators:
4730:
4729:
4726:
4723:
4721:
4717:
4714:
4713:
4711:
4709:
4705:
4695:
4692:
4689:
4688:
4686:
4682:
4676:
4673:
4670:
4666:
4662:
4658:
4654:
4650:
4646:
4642:
4639:
4637:
4634:
4631:
4630:
4628:
4626:
4622:
4615:
4612:
4609:
4608:
4605:
4602:
4600:
4597:
4595:
4594:Selpercatinib
4592:
4589:
4585:
4581:
4577:
4573:
4569:
4565:
4561:
4558:
4556:
4553:
4550:
4549:
4547:
4545:
4541:
4535:
4532:
4529:
4528:
4525:
4522:
4520:
4517:
4514:
4513:
4510:
4507:
4505:
4502:
4500:
4499:Selpercatinib
4497:
4495:
4492:
4490:
4487:
4484:
4480:
4476:
4472:
4468:
4464:
4460:
4456:
4452:
4448:
4444:
4440:
4436:
4432:
4428:
4425:
4423:
4420:
4417:
4416:
4414:
4412:
4408:
4402:
4399:
4397:
4394:
4392:
4391:Selpercatinib
4389:
4387:
4384:
4381:
4377:
4373:
4369:
4365:
4361:
4357:
4353:
4349:
4345:
4342:
4340:
4337:
4334:
4333:
4331:
4329:
4325:
4322:
4320:
4316:
4305:
4301:
4297:
4293:
4289:
4285:
4282:
4280:
4277:
4275:
4272:
4270:
4267:
4264:
4263:
4261:
4259:
4255:
4249:
4246:
4244:
4241:
4239:
4236:
4233:
4232:
4228:
4224:
4220:
4216:
4213:
4210:
4209:
4207:
4205:
4201:
4195:
4192:
4190:
4187:
4185:
4182:
4180:
4177:
4175:
4172:
4169:
4168:
4165:
4162:
4160:
4157:
4155:
4152:
4150:
4147:
4145:
4142:
4140:
4137:
4134:
4133:
4130:
4126:
4123:
4122:
4120:
4118:
4114:
4108:
4105:
4103:
4100:
4098:
4095:
4093:
4090:
4088:
4085:
4083:
4080:
4078:
4075:
4073:
4070:
4068:
4067:Depatuxizumab
4065:
4063:
4060:
4057:
4056:
4053:
4050:
4048:
4045:
4043:
4040:
4038:
4035:
4033:
4030:
4028:
4025:
4023:
4020:
4018:
4015:
4013:
4010:
4008:
4005:
4003:
4000:
3998:
3995:
3993:
3990:
3988:
3985:
3982:
3981:
3978:
3975:
3973:
3970:
3968:
3965:
3963:
3960:
3958:
3955:
3953:
3950:
3948:
3945:
3943:
3940:
3938:
3934:
3931:
3930:
3928:
3926:
3918:
3915:
3913:
3909:
3903:
3900:
3898:
3895:
3893:
3890:
3887:
3886:
3884:
3882:
3878:
3871:
3868:
3865:
3862:
3859:
3858:
3855:
3852:
3850:
3847:
3845:
3842:
3839:
3838:
3835:
3832:
3830:
3827:
3824:
3823:
3820:
3817:
3815:
3812:
3809:
3808:
3806:
3804:
3800:
3796:
3793:
3786:
3781:
3779:
3774:
3772:
3767:
3766:
3763:
3751:
3748:
3746:
3743:
3741:
3738:
3736:
3733:
3731:
3728:
3726:
3723:
3721:
3718:
3716:
3713:
3711:
3708:
3706:
3703:
3701:
3698:
3696:
3693:
3691:
3688:
3686:
3683:
3681:
3678:
3676:
3673:
3671:
3668:
3666:
3665:Larotrectinib
3663:
3661:
3658:
3656:
3653:
3651:
3648:
3646:
3643:
3641:
3638:
3634:
3631:
3629:
3626:
3624:
3621:
3619:
3616:
3614:
3611:
3610:
3609:
3606:
3602:
3599:
3597:
3594:
3593:
3592:
3590:
3586:
3582:
3579:
3577:
3574:
3572:
3569:
3567:
3564:
3562:
3559:
3558:
3557:
3556:
3552:
3548:
3545:
3543:
3540:
3538:
3535:
3534:
3533:
3531:
3527:
3523:
3520:
3518:
3517:Ridaforolimus
3515:
3513:
3510:
3509:
3508:
3507:
3503:
3500:
3496:
3495:
3491:
3487:
3484:
3480:
3479:
3475:
3471:
3467:
3464:
3460:
3459:
3455:
3451:
3450:
3448:
3444:
3432:
3429:
3427:
3426:Pirtobrutinib
3424:
3422:
3421:Orelabrutinib
3419:
3417:
3414:
3412:
3411:Acalabrutinib
3409:
3408:
3407:
3406:
3402:
3401:
3396:
3393:
3391:
3388:
3386:
3383:
3382:
3381:
3380:
3376:
3372:
3371:
3366:
3363:
3361:
3358:
3356:
3353:
3351:
3348:
3347:
3346:
3345:
3341:
3340:
3335:
3332:
3330:
3327:
3325:
3322:
3320:
3317:
3315:
3312:
3310:
3307:
3305:
3302:
3301:
3300:
3299:
3295:
3294:
3290:
3287:
3285:
3281:
3280:
3276:
3275:
3270:
3267:
3265:
3262:
3260:
3257:
3255:
3252:
3250:
3247:
3245:
3242:
3240:
3237:
3236:
3235:
3234:
3230:
3229:
3227:
3225:
3221:
3214:
3210:
3206:
3203:
3201:
3197:
3196:
3192:
3188:
3187:Selpercatinib
3184:
3183:Repotrectinib
3180:
3176:
3172:
3171:Larotrectinib
3168:
3164:
3160:
3157:
3155:
3151:
3150:
3145:
3142:
3140:
3137:
3135:
3132:
3131:
3130:
3129:
3125:
3124:
3119:
3116:
3114:
3111:
3109:
3106:
3104:
3101:
3099:
3096:
3094:
3091:
3089:
3086:
3084:
3081:
3079:
3076:
3074:
3071:
3069:
3066:
3064:
3061:
3059:
3056:
3055:
3054:
3053:
3049:
3048:
3044:
3040:
3036:
3035:
3031:
3028:
3025:
3023:
3020:
3018:
3015:
3013:
3010:
3008:
3005:
3003:
3000:
2998:
2995:
2993:
2989:
2988:
2984:
2979:
2978:RTK class III
2976:
2975:
2970:
2967:
2965:
2962:
2960:
2957:
2956:
2955:
2954:
2949:
2948:
2944:
2941:
2939:
2936:
2934:
2931:
2929:
2926:
2924:
2921:
2919:
2916:
2914:
2911:
2909:
2906:
2904:
2901:
2899:
2896:
2894:
2891:
2889:
2886:
2884:
2880:
2879:
2874:
2871:
2870:
2868:
2866:
2862:
2859:
2856:
2852:
2842:
2839:
2837:
2834:
2832:
2829:
2827:
2824:
2822:
2819:
2817:
2814:
2812:
2809:
2807:
2804:
2802:
2799:
2797:
2794:
2792:
2789:
2787:
2784:
2782:
2779:
2777:
2774:
2772:
2769:
2767:
2764:
2762:
2761:Pembrolizumab
2759:
2757:
2754:
2752:
2749:
2747:
2744:
2742:
2739:
2737:
2734:
2732:
2729:
2727:
2726:Mogamulizumab
2724:
2722:
2719:
2717:
2714:
2712:
2709:
2707:
2704:
2702:
2699:
2697:
2694:
2692:
2689:
2687:
2684:
2682:
2679:
2677:
2674:
2672:
2669:
2667:
2664:
2662:
2659:
2657:
2654:
2652:
2649:
2647:
2644:
2642:
2639:
2637:
2634:
2631:
2627:
2624:
2622:
2619:
2618:
2616:
2612:
2605:
2601:
2600:
2595:
2592:
2591:
2587:
2583:
2582:
2577:
2573:
2572:
2567:
2564:
2562:
2559:
2557:
2554:
2552:
2549:
2547:
2546:Mosunetuzumab
2544:
2542:
2539:
2537:
2533:
2532:
2527:
2526:Mosunetuzumab
2523:
2519:
2515:
2514:
2509:
2506:
2505:
2503:
2501:
2497:
2493:
2486:
2482:
2481:
2477:
2474:
2471:
2469:
2465:
2464:
2460:
2459:
2457:
2453:
2446:
2443:
2441:
2438:
2435:
2431:
2427:
2423:
2422:
2418:
2415:
2412:
2410:
2406:
2405:
2400:
2397:
2396:
2394:
2392:
2388:
2385:
2382:
2379:
2375:
2370:
2366:
2362:
2355:
2350:
2348:
2343:
2341:
2336:
2335:
2332:
2324:
2320:
2316:
2312:
2311:
2306:
2301:
2300:
2296:
2287:
2283:
2278:
2273:
2269:
2265:
2261:
2257:
2253:
2246:
2243:
2240:
2236:
2235:
2228:
2225:
2212:
2208:
2202:
2199:
2188:
2184:
2180:
2179:The Economist
2176:
2170:
2167:
2162:
2158:
2153:
2148:
2144:
2140:
2136:
2132:
2131:JAMA Oncology
2128:
2121:
2118:
2106:
2104:
2098:
2092:
2089:
2076:
2072:
2068:
2061:
2058:
2046:on 2 May 2012
2045:
2041:
2040:Health Canada
2037:
2031:
2028:
2023:
2019:
2015:
2011:
2007:
2003:
1999:
1995:
1988:
1985:
1973:
1967:
1964:
1959:
1953:
1950:
1939:on 2015-02-04
1938:
1934:
1928:
1925:
1914:on 2022-01-11
1913:
1909:
1903:
1900:
1895:
1891:
1885:
1883:
1879:
1868:on 2020-12-01
1867:
1863:
1857:
1854:
1851:
1847:
1846:
1839:
1836:
1833:
1829:
1828:
1821:
1818:
1811:
1807:
1803:
1798:
1797:
1794:
1790:
1785:
1780:
1776:
1772:
1768:
1764:
1760:
1753:
1750:
1739:on 2013-01-27
1738:
1734:
1730:
1723:
1720:
1715:
1711:
1707:
1703:
1699:
1695:
1691:
1687:
1680:
1677:
1672:
1671:
1666:
1659:
1656:
1644:
1638:
1635:
1630:
1626:
1622:
1616:
1613:
1608:
1604:
1599:
1594:
1590:
1586:
1582:
1578:
1574:
1570:
1566:
1559:
1556:
1551:
1547:
1542:
1537:
1533:
1529:
1525:
1521:
1517:
1513:
1509:
1502:
1499:
1492:
1488:
1484:
1483:
1480:
1476:
1471:
1466:
1462:
1458:
1454:
1450:
1446:
1442:
1438:
1431:
1428:
1423:
1419:
1414:
1409:
1405:
1401:
1397:
1393:
1389:
1382:
1379:
1374:
1370:
1365:
1360:
1356:
1352:
1348:
1344:
1340:
1333:
1330:
1325:
1321:
1316:
1311:
1307:
1303:
1299:
1292:
1289:
1284:
1280:
1276:
1272:
1268:
1264:
1260:
1256:
1248:
1245:
1240:
1236:
1231:
1226:
1222:
1218:
1214:
1210:
1206:
1202:
1198:
1191:
1187:
1181:
1179:
1177:
1175:
1171:
1166:
1162:
1156:
1154:
1150:
1143:
1141:
1138:
1130:
1128:
1126:
1118:
1116:
1114:
1110:
1105:
1103:
1099:
1096:
1092:
1087:
1084:
1082:
1074:
1069:
1067:
1065:
1061:
1056:
1054:
1050:
1049:MEK-inhibitor
1046:
1041:
1038:
1036:
1031:
1029:
1025:
1021:
1016:
1013:
1011:
1003:
1001:
998:
989:
984:
981:secretion of
980:
977:
974:
970:
966:
963:
959:
958:
957:
951:
949:
947:
946:glutamic acid
943:
939:
934:
932:
928:
924:
920:
912:
910:
908:
904:
901:
897:
893:
889:
885:
881:
872:
868:
866:
862:
857:
851:
845:
842:
838:
833:
830:
827:
825:
821:
818:
815:
813:
809:
806:
803:
799:
794:
790:
786:
781:
776:
773:
769:
764:
755:
748:
739:
734:
730:
723:
714:
710:
703:
696:
692:
691:
689:
686:
681:
674:
672:
668:
629:
627:
623:
618:
614:
610:
607:
605:
603:ECHA InfoCard
599:
591:
587:
583:
582:
580:
571:
567:
559:
558:RCSB PDB
553:
548:
547:
545:
543:
539:
532:
531:ChEMBL1229517
528:
527:
525:
523:
519:
512:
508:
507:
505:
503:
499:
492:
488:
487:
485:
483:
479:
472:
468:
467:
465:
463:
459:
452:
448:
447:
445:
443:
439:
432:
428:
427:
425:
423:
419:
412:
408:
407:
405:
398:
394:
387:
383:
382:
380:
378:
374:
366:
362:
358:
351:
346:
340:
330:
327:
317:
315:
306:
303:
293:
292:
290:
288:
284:
279:
271:
266:
263:
262:
260:
258:
254:
251:
248:
246:
240:
234:
225:
224:
222:
220:
214:
207:
203:
193:
190:
185:
176:
175:
173:
171:
167:
163:
159:
157:
153:
149:
145:
143:
139:
135:
131:
127:
123:
121:
117:
113:
112:
99:
52:
50:Pronunciation
48:
45:Clinical data
43:
39:
34:
30:
25:
6777:Chemotherapy
6772:Sulfonamides
6767:Fluoroarenes
6693:Cerebrolysin
6689:
6663:Pleiotrophin
6619:Interleukins
6532:
6513:
6483:
6402:Fruquintinib
6392:Cabozantinib
6373:
6363:
6321:
6285:Lestaurtinib
6236:
6216:
6184:Lestaurtinib
6135:
6125:
6106:Antagonists:
6105:
6039:Deoxygedunin
5994:3,7,8,2'-THF
5985:
5964:
5955:Against NGF:
5954:
5951:
5907:Against NGF:
5906:
5899:
5896:
5859:Lestaurtinib
5810:
5800:
5794:Testosterone
5776:Antagonists:
5775:
5725:
5625:
5610:
5585:
5566:
5556:
5535:
5525:
5504:
5494:
5473:
5458:
5418:
5333:
5301:
5280:
5271:Against NGF:
5270:
5267:
5223:Against NGF:
5222:
5219:
5213:Testosterone
5195:Antagonists:
5194:
5144:
5114:
5075:
5050:
5039:
5016:Teprotumumab
4977:
4947:
4906:
4855:Ficlatuzumab
4850:Emibetuzumab
4846:
4800:JNJ-38877605
4770:Cabozantinib
4741:
4731:
4720:Fosgonimeton
4715:
4690:
4632:
4610:
4551:
4534:Infigratinib
4530:
4515:
4418:
4335:
4269:Betacellulin
4265:
4248:Seribantumab
4234:
4211:
4170:
4135:
4129:Unknown/none
4128:
4124:
4058:
3983:
3942:Betacellulin
3937:Amphiregulin
3932:
3924:(ErbB1/HER1)
3888:
3860:
3840:
3826:Antagonists:
3825:
3810:
3803:Angiopoietin
3705:Pexidartinib
3690:Odronextamab
3660:Gilteritinib
3640:Cabozantinib
3587:
3553:
3528:
3522:Temsirolimus
3504:
3488:
3470:proapoptotic
3468:
3452:
3431:Zanubrutinib
3403:
3373:
3342:
3319:Lestaurtinib
3298:Janus kinase
3296:
3277:
3231:
3224:Non-receptor
3205:Cabozantinib
3198:
3167:Infigratinib
3152:
3126:
3068:Fruquintinib
3050:
3043:Gilteritinib
3039:Lestaurtinib
3032:
2981:
2950:
2923:Mobocertinib
2888:Aumolertinib
2876:
2841:Tremelimumab
2826:Tislelizumab
2781:Retifanlimab
2656:Blinatumomab
2626:Atezolizumab
2597:
2579:
2569:
2551:Obinutuzumab
2529:
2511:
2478:
2461:
2419:
2402:
2309:
2259:
2255:
2245:
2232:
2227:
2215:. Retrieved
2210:
2201:
2190:. Retrieved
2178:
2169:
2134:
2130:
2120:
2109:. Retrieved
2100:
2091:
2081:February 18,
2079:. Retrieved
2075:the original
2070:
2060:
2048:. Retrieved
2044:the original
2039:
2030:
1997:
1993:
1987:
1976:. Retrieved
1966:
1952:
1941:. Retrieved
1937:the original
1927:
1916:. Retrieved
1912:the original
1902:
1893:
1870:. Retrieved
1866:the original
1856:
1843:
1838:
1825:
1820:
1810:the original
1805:
1766:
1762:
1752:
1741:. Retrieved
1737:the original
1732:
1727:Flaherty K.
1722:
1689:
1685:
1679:
1668:
1658:
1647:. Retrieved
1637:
1628:
1624:
1615:
1572:
1568:
1558:
1515:
1511:
1501:
1490:
1444:
1440:
1430:
1395:
1391:
1381:
1346:
1342:
1332:
1305:
1301:
1291:
1258:
1254:
1247:
1204:
1200:
1164:
1134:
1122:
1106:
1088:
1085:
1078:
1075:Legal status
1057:
1042:
1039:
1032:
1017:
1014:
1007:
993:
990:Side effects
979:Stromal cell
955:
935:
916:
887:
879:
878:
771:
751:
364:
287:Legal status
281:Legal status
170:License data
6653:Oncomodulin
6517:Aflibercept
6507:Ranibizumab
6502:Ramucirumab
6492:Bevacizumab
6484:Antibodies:
6442:Regorafenib
6382:Altiratinib
6295:ONO-5390556
6265:Entrectinib
6240:Altiratinib
6194:ONO-5390556
6164:Entrectinib
6139:Altiratinib
5925:Frunevetmab
5897:Antibodies:
5874:ONO-5390556
5839:Entrectinib
5814:Altiratinib
5769:Tavilermide
5664:Quizartinib
5603:SCF (c-Kit)
5427:Ramucirumab
5419:Antibodies:
5392:Quizartinib
5342:Avapritinib
5305:Becaplermin
5241:Frunevetmab
5220:Antibodies:
5123:Trofinetide
5054:Dusigitumab
5051:Antibodies:
5006:Robatumumab
4996:Figitumumab
4991:Dalotuzumab
4986:Cixutumumab
4978:Antibodies:
4870:Rilotumumab
4865:Onartuzumab
4860:Flanvotumab
4847:Antibodies:
4815:PF-04217903
4745:Altiratinib
4708:HGF (c-Met)
4611:Antibodies:
4516:Antibodies:
4238:Duligotumab
4235:Antibodies:
4149:Trastuzumab
4139:Ertumaxomab
4136:Antibodies:
4107:Zalutumumab
4102:Panitumumab
4097:Nimotuzumab
4092:Necitumumab
4082:Imgatuzumab
4059:Antibodies:
4042:Osimertinib
4007:Dacomitinib
3902:Dapiclermin
3861:Antibodies:
3844:Altiratinib
3735:Tebentafusp
3715:Regorafenib
3710:Quizartinib
3700:Pemigatinib
3680:Midostaurin
3655:Erdafitinib
3650:Entrectinib
3633:Parsaclisib
3581:Trilaciclib
3571:Palbociclib
3566:Dalpiciclib
3561:Abemaciclib
3463:Aflibercept
3390:Entrectinib
3360:Selumetinib
3355:Cobimetinib
3350:Binimetinib
3334:Ruxolitinib
3324:Momelotinib
3304:Baricitinib
3202:inhibitors:
3179:Pralsetinib
3175:Pemigatinib
3163:Futibatinib
3159:Entrectinib
3156:inhibitors:
3088:Regorafenib
2992:Avapritinib
2938:Rociletinib
2933:Osimertinib
2898:Dacomitinib
2836:Toripalimab
2821:Teclistamab
2811:Talquetamab
2806:Tafasitamab
2801:Sugemalimab
2796:Serplulimab
2786:Sabatolimab
2776:Ramucirumab
2771:Prolgolimab
2741:Necitumumab
2696:Epcoritamab
2676:Dostarlimab
2666:Daratumumab
2621:Amivantamab
2586:Alemtuzumab
2576:Brentuximab
2566:Tositumomab
2541:Ibritumomab
2522:Elranatamab
2485:Bevacizumab
2473:Edrecolomab
2468:Catumaxomab
2430:Trastuzumab
2414:Panitumumab
2234:NCT03410875
1845:NCT00949702
1827:NCT00405587
1045:cobimetinib
1035:dacarbazine
880:Vemurafenib
766:vemurafenib
678: g·mol
609:100.287.801
386:918504-65-1
348:Identifiers
206:Vemurafenib
156:MedlinePlus
129:Other names
120:Trade names
21:Vemurafenib
6731:Categories
6472:Vandetanib
6437:Rebastinib
6432:Pegaptanib
6422:Nintedanib
6412:Lenvatinib
6377:Agerafenib
6330:Ripretinib
6255:CH-7057288
6154:CH-7057288
6019:7,8,3'-THF
6014:7,8,2'-THF
5940:Ranevetmab
5930:Fulranumab
5884:Rebastinib
5829:CH-7057288
5744:Cenegermin
5629:Agerafenib
5589:Agerafenib
5570:Vandetanib
5539:Vandetanib
5508:Vandetanib
5477:Vandetanib
5422:Olaratumab
5397:Ripretinib
5377:Nintedanib
5362:Lenvatinib
5352:Crenolanib
5337:Agerafenib
5256:Ranevetmab
5246:Fulranumab
5163:Cenegermin
5137:LNGF (p75)
5059:Xentuzumab
5021:Xentuzumab
4966:NVP-AEW541
4961:NVP-ADW742
4956:Linsitinib
4951:BMS-754807
4936:Mecasermin
4835:Tivantinib
4825:PHA-665752
4820:PF-2341066
4790:Golvatinib
4780:Crizotinib
4775:Capmatinib
4765:BMS-777607
4760:Amuvatinib
4636:Ersofermin
4599:Sprifermin
4555:Ersofermin
4504:Sprifermin
4494:Repifermin
4489:Palifermin
4422:Ersofermin
4401:Velafermin
4386:Repifermin
4339:Ersofermin
4258:ErbB4/HER4
4243:Patritumab
4204:ErbB3/HER3
4184:Mubritinib
4144:Pertuzumab
4117:ErbB2/HER2
4047:Vandetanib
4002:Canertinib
3997:Brigatinib
3992:Agerafenib
3972:Nepidermin
3967:Murodermin
3957:Epiregulin
3912:EGF (ErbB)
3870:Nesvacumab
3864:Evinacumab
3854:Rebastinib
3795:modulators
3750:Venetoclax
3745:Vandetanib
3720:Ripretinib
3685:Nintedanib
3670:Lenvatinib
3645:Capmatinib
3628:Idelalisib
3618:Copanlisib
3591:inhibitors
3576:Ribociclib
3547:Vismodegib
3532:inhibitors
3512:Everolimus
3478:prohibitin
3395:Lorlatinib
3385:Crizotinib
3365:Trametinib
3329:Pacritinib
3314:Filgotinib
3309:Fedratinib
3213:Crizotinib
3209:Capmatinib
3191:Vandetanib
3139:Brigatinib
3118:Vandetanib
3078:Nintedanib
3073:Lenvatinib
3012:Ripretinib
2943:Vandetanib
2918:Lazertinib
2893:Brigatinib
2816:Tarlatamab
2751:Olaratumab
2711:Isatuximab
2706:Ipilimumab
2686:Elotuzumab
2681:Durvalumab
2661:Cemiplimab
2651:Bermekimab
2641:Axatilimab
2556:Ofatumumab
2536:Glofitamab
2518:Glofitamab
2426:Pertuzumab
2192:2016-04-15
2111:2018-05-20
1978:2011-08-17
1943:2015-02-04
1918:2012-12-17
1872:2011-02-03
1743:2010-09-10
1649:2009-06-07
1144:References
1064:trametinib
1060:dabrafenib
997:arthralgia
952:Resistance
938:amino acid
892:medication
793:C-terminus
789:N-terminus
683:3D model (
671:Molar mass
542:PDB ligand
491:207SMY3FQT
462:ChemSpider
422:IUPHAR/BPS
377:CAS Number
357:IUPAC name
6497:Icrucumab
6477:WHI-P 154
6467:Tivozanib
6462:Toceranib
6457:Sunitinib
6452:Sorafenib
6447:Semaxanib
6427:Pazopanib
6417:Motesanib
6407:Lapatinib
6397:Cediranib
6335:Telbermin
6322:Agonists:
6270:GZ-389988
6250:CE-245677
6217:Agonists:
6169:GZ-389988
6149:CE-245677
6049:Diosmetin
5986:Agonists:
5952:Aptamers:
5945:Tanezumab
5920:Fasinumab
5864:Milciclib
5844:GZ-389988
5824:CE-245677
5726:Agonists:
5679:Toceranib
5674:Sunitinib
5669:Sorafenib
5659:Pazopanib
5654:Nilotinib
5649:Masitinib
5639:Dasatinib
5611:Agonists:
5557:Agonists:
5526:Agonists:
5495:Agonists:
5467:Liatermin
5459:Agonists:
5442:RET (GFL)
5432:Tovetumab
5412:Toceranib
5407:Sorafenib
5402:Sunitinib
5387:Radotinib
5382:Pazopanib
5372:Motesanib
5367:Masitinib
5302:Agonists:
5268:Aptamers:
5261:Tanezumab
5236:Fasinumab
5145:Agonists:
5001:Ganitumab
4921:IGF-1 LR3
4840:Volitinib
4795:INCB28060
4785:Foretinib
4691:Agonists:
4675:Trafermin
4633:Agonists:
4614:Burosumab
4604:Trafermin
4552:Agonists:
4519:Aprutumab
4509:Trafermin
4471:10 (KGF2)
4419:Agonists:
4396:Trafermin
4376:10 (KGF2)
4336:Agonists:
4266:Agonists:
4212:Agonists:
4194:Tucatinib
4189:Neratinib
4179:Lapatinib
4087:Matuzumab
4077:Futuximab
4062:Cetuximab
4052:WHI-P 154
4037:Neratinib
4032:Lapatinib
4022:Grandinin
4017:Gefitinib
4012:Erlotinib
3889:Agonists:
3849:CE-245677
3811:Agonists:
3740:Tepotinib
3730:Sunitinib
3725:Sorafenib
3695:Pazopanib
3675:Masitinib
3623:Duvelisib
3613:Alpelisib
3601:Sotorasib
3596:Adagrasib
3542:Sonidegib
3537:Glasdegib
3483:Adipotide
3416:Ibrutinib
3289:Dasatinib
3284:Bosutinib
3269:Radotinib
3264:Ponatinib
3259:Nilotinib
3249:Dasatinib
3244:Bosutinib
3239:Asciminib
3207:(VEGFR),
3165:(FGFR2),
3144:Ceritinib
3134:Alectinib
3113:Toceranib
3108:Tivozanib
3103:Sunitinib
3098:Sorafenib
3093:Semaxanib
3083:Pazopanib
3063:Cediranib
3027:Toceranib
3022:Sunitinib
3017:Sorafenib
3007:Pazopanib
3002:Masitinib
2969:Tucatinib
2964:Neratinib
2959:Lapatinib
2928:Olmutinib
2908:Gefitinib
2903:Erlotinib
2878:HER1/EGFR
2746:Nivolumab
2736:Naxitamab
2561:Rituximab
2409:Cetuximab
2404:HER1/EGFR
2211:HCLF Blog
2187:0013-0613
2071:Onco'Zine
1193:;
1026:), and a
967:A second
907:Plexxikon
843:ligand id
243:Routes of
217:Pregnancy
148:Monograph
142:Drugs.com
6721:Medicine
6679:instead)
6668:Renalase
6629:instead)
6600:instead)
6547:instead)
6387:Axitinib
6356:D (FIGF)
6300:PLX-7486
6290:ONO-4474
6245:AZD-6918
6199:PLX-7486
6189:ONO-4474
6144:AZD-6918
6126:Ligands:
6044:Deprenyl
6004:7,3'-DHF
5935:MEDI-578
5915:ASP-6294
5879:PLX-7486
5869:ONO-4474
5819:AZD-6918
5779:ALE-0540
5700:instead.
5644:Imatinib
5634:Axitinib
5614:Ancestim
5579:Unsorted
5357:Imatinib
5347:Axitinib
5251:MEDI-578
5231:ASP-6294
5198:ALE-0540
5040:Agonists
4981:AVE-1642
4907:Agonists
4830:SU-11274
4716:Agonists
4694:FGF15/19
4684:Unsorted
4649:2 (bFGF)
4568:2 (bFGF)
4435:2 (bFGF)
4352:2 (bFGF)
4174:Afatinib
4125:Agonists
4027:Icotinib
3987:Afatinib
3933:Agonists
3530:hedgehog
3492:against
3490:exotoxin
3456:against
3405:Bruton's
3254:Imatinib
3177:(FGFR),
3173:(NTRK),
3058:Axitinib
2997:Axitinib
2953:HER2/neu
2913:Icotinib
2883:Afatinib
2857:("-nib")
2636:Avelumab
2508:lymphoid
2500:lymphoma
2496:Leukemia
2421:HER2/neu
2383:("-mab")
2323:28809522
2317:(NCBI).
2286:35930750
2217:July 25,
2161:29188284
2050:21 April
2014:23060265
1793:20818844
1714:20019269
1607:22763448
1550:22763439
1479:21107323
1422:20149136
1373:20130576
1324:25520039
1283:16031942
1275:18458053
1239:20823850
1119:Research
1098:mutation
1028:phase II
969:oncogene
923:melanoma
896:melanoma
888:Zelboraf
856:RCSB PDB
805:melanoma
791:= blue,
754:(verify)
471:24747352
442:DrugBank
411:42611257
257:ATC code
250:By mouth
219:category
124:Zelboraf
6556:Ephrins
6260:DS-6051
6159:DS-6051
6064:LM22A-4
6054:DMAQ-B1
6009:7,8-DHF
5989:3,7-DHF
5958:RBM-004
5903:GBR-900
5834:DS-6051
5804:VM-902A
5274:RBM-004
4971:OSl-906
4931:Insulin
4810:MK-2461
4755:AMG-458
3892:Axokine
3233:bcr-abl
2594:myeloid
2277:9935554
2152:5844839
2022:9337155
1960:. 2015.
1806:Corante
1784:3724529
1694:Bibcode
1686:Science
1598:3724525
1577:Bibcode
1541:3711467
1520:Bibcode
1470:3143360
1449:Bibcode
1413:2848976
1351:Bibcode
1230:2948082
1209:Bibcode
1020:Phase I
1004:History
971:called
929:on the
890:, is a
865:LIGPLOT
626:Formula
451:DB08881
397:PubChem
312::
273:)
267: (
265:L01XE15
232: D
204::
186::
162:a612009
6707:Portal
6526:Others
6220:BNN-20
6109:ANA-12
6034:BNN-20
5754:DHEA-S
5739:BNN-27
5734:BNN-20
5173:DHEA-S
5158:BNN-27
5153:BNN-20
5069:Others
4274:Epigen
3952:Epigen
2480:VEGF-A
2321:
2284:
2274:
2185:
2159:
2149:
2020:
2012:
1791:
1781:
1712:
1605:
1595:
1569:Nature
1548:
1538:
1512:Nature
1477:
1467:
1441:Nature
1420:
1410:
1371:
1343:Nature
1322:
1281:
1273:
1237:
1227:
1201:Nature
985:(HGF).
962:PDGFRB
942:valine
903:enzyme
709:SMILES
676:489.92
522:ChEMBL
511:D09996
339:℞-only
337:
324:
314:℞-only
300:
199:
189:by INN
182:
114:
111:-ə-nib
6675:(see
6625:(see
6596:(see
6543:(see
6275:K252a
6174:K252a
5849:K252a
5789:FX007
5549:GFRα4
5518:GFRα3
5487:GFRα2
5451:GFRα1
5079:IGFBP
5032:IGF-2
5011:R1507
4899:IGF-1
4805:K252a
4625:FGFR4
4544:FGFR3
4411:FGFR2
4328:FGFR1
3474:ANXA2
3446:Other
3344:MAP2K
3215:(ALK)
3200:c-MET
3052:VEGFR
2987:PDGFR
2983:C-kit
2614:Other
2463:EpCAM
2256:Blood
2105:(FDA)
2101:U.S.
2018:S2CID
1279:S2CID
1095:V600E
1047:), a
1008:In a
900:B-Raf
846:032:
729:InChI
685:JSmol
549:032 (
6677:here
6627:here
6598:here
6545:here
6340:VEGF
6314:VEGF
6230:NT-3
6225:DHEA
6209:TrkC
6129:DHEA
6099:TDP6
6079:NT-4
6074:NT-3
6059:HIOC
6029:BDNF
5978:TrkB
5749:DHEA
5718:TrkA
5698:here
5696:See
5689:TGFβ
5294:PDGF
5188:NT-4
5183:NT-3
5168:DHEA
5148:BDNF
3897:CNTF
3881:CNTF
3589:KRAS
3494:IL-2
3476:and
3458:VEGF
3375:EML4
3034:FLT3
2985:and
2873:ErbB
2599:CD33
2581:CD52
2571:CD30
2531:CD20
2399:ErbB
2319:PMID
2282:PMID
2219:2022
2183:ISSN
2157:PMID
2083:2013
2052:2012
2010:PMID
1789:PMID
1710:PMID
1603:PMID
1546:PMID
1475:PMID
1418:PMID
1369:PMID
1320:PMID
1271:PMID
1235:PMID
1190:3OG7
1062:and
973:NRAS
871:3og7
850:PDBe
817:BRAF
552:PDBe
502:KEGG
482:UNII
431:5893
138:AHFS
6094:R13
5764:NGF
5709:Trk
5178:NGF
4890:IGF
4750:AM7
4641:FGF
4560:FGF
4461:),
4459:KGF
4427:FGF
4344:FGF
4319:FGF
3921:EGF
3379:ALK
3279:Src
3154:RET
3128:ALK
2578:),
2568:),
2528:),
2513:CD3
2369:L01
2272:PMC
2264:doi
2260:140
2147:PMC
2139:doi
2002:doi
1779:PMC
1771:doi
1767:363
1702:doi
1690:326
1593:PMC
1585:doi
1573:487
1536:PMC
1528:doi
1516:487
1465:PMC
1457:doi
1445:468
1408:PMC
1400:doi
1359:doi
1347:464
1310:doi
1263:doi
1225:PMC
1217:doi
1205:467
1186:PDB
921:in
884:INN
841:PDB
575:EPA
401:CID
326:POM
270:WHO
202:FDA
184:EMA
109:RAF
107:-ə-
105:VEM
6733::
6588:B3
6586:,
6584:B2
6582:,
6580:B1
6578:,
6576:A5
6574:,
6572:A4
6570:,
6568:A3
6566:,
6564:A2
6562:,
6560:A1
6354:,
6350:,
6346:,
6089:R7
5905:;
5324:,
5320:,
5316:,
5105:,
5101:,
5097:,
5093:,
5089:,
5085:,
5042::
4909::
4718::
4669:19
4667:,
4663:,
4659:,
4655:,
4651:,
4647:,
4588:23
4586:,
4584:18
4582:,
4578:,
4574:,
4570:,
4566:,
4483:22
4481:,
4479:18
4477:,
4475:17
4473:,
4469:,
4465:,
4453:,
4449:,
4445:,
4441:,
4437:,
4433:,
4380:20
4378:,
4374:,
4370:,
4366:,
4362:,
4358:,
4354:,
4350:,
4302:,
4298:,
4294:,
4290:,
4225:,
4221:,
4127::
3935::
3211:,
3181:,
3169:,
3041:,
2980::
2875::
2596::
2524:,
2520:,
2510::
2428:,
2401::
2378:CI
2363:/
2313:.
2280:.
2270:.
2258:.
2254:.
2209:.
2177:.
2155:.
2145:.
2133:.
2129:.
2099:.
2069:.
2038:.
2016:.
2008:.
1998:11
1996:.
1892:.
1881:^
1787:.
1777:.
1765:.
1761:.
1731:.
1708:.
1700:.
1688:.
1667:.
1627:.
1623:.
1601:.
1591:.
1583:.
1571:.
1567:.
1544:.
1534:.
1526:.
1514:.
1510:.
1489:.
1473:.
1463:.
1455:.
1443:.
1439:.
1416:.
1406:.
1396:23
1394:.
1390:.
1367:.
1357:.
1345:.
1341:.
1318:.
1306:95
1304:.
1300:.
1277:.
1269:.
1257:.
1233:.
1223:.
1215:.
1203:.
1199:.
1188::
1173:^
1163:.
1152:^
1127:.
909:.
853:,
643:Cl
640:18
634:23
555:,
333:US
320:UK
309:CA
302:S4
296:AU
228:AU
196:US
179:EU
6709::
6621:/
6590:)
6558:(
6358:)
6352:C
6348:B
6344:A
6342:(
5891:)
5328:)
5326:D
5322:C
5318:B
5314:A
5312:(
5109:)
5107:7
5103:6
5099:5
5095:4
5091:3
5087:2
5083:1
5081:(
4671:)
4665:9
4661:8
4657:6
4653:4
4645:1
4643:(
4590:)
4580:9
4576:8
4572:4
4564:1
4562:(
4485:)
4467:9
4463:8
4457:(
4455:7
4451:6
4447:5
4443:4
4439:3
4431:1
4429:(
4382:)
4372:8
4368:6
4364:5
4360:4
4356:3
4348:1
4346:(
4306:)
4300:4
4296:3
4292:2
4288:1
4286:(
4229:)
4223:2
4219:1
4217:(
3784:e
3777:t
3770:v
3501:)
3497:(
3485:)
3481:(
3465:)
3461:(
3377:-
3291:)
3282:(
3037:(
3029:)
2990:(
2945:)
2881:(
2632:)
2628:(
2606:)
2602:(
2588:)
2584:(
2574:(
2534:(
2516:(
2498:/
2487:)
2483:(
2475:)
2466:(
2447:)
2436:)
2432:(
2424:(
2416:)
2407:(
2371:)
2367:(
2353:e
2346:t
2339:v
2288:.
2266::
2221:.
2195:.
2163:.
2141::
2135:4
2114:.
2085:.
2054:.
2024:.
2004::
1981:.
1946:.
1921:.
1875:.
1795:.
1773::
1746:.
1716:.
1704::
1696::
1673:.
1652:.
1629:5
1609:.
1587::
1579::
1552:.
1530::
1522::
1481:.
1459::
1451::
1424:.
1402::
1375:.
1361::
1353::
1326:.
1312::
1285:.
1265::
1259:6
1241:.
1219::
1211::
882:(
687:)
664:S
661:3
658:O
655:3
652:N
649:2
646:F
637:H
631:C
577:)
573:(
561:)
365:N
335::
322::
298::
230::
140:/
98:/
95:b
92:ɪ
89:n
86:ə
83:f
80:æ
77:r
74:ˈ
71:ə
68:m
65:ɛ
62:v
59:ˌ
56:/
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
